Implication of 5-HT2 receptor subtypes in the mechanism of action of the GABAergic compound etifoxine in the four-plate test in Swiss mice

Behavioural Brain Research

Volumn 208, Issue 2, 2010, Pages 352-358

  Bourin, Michel ^a   Hascoët, Martine ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

5 HT2 ligands; Anxiety; Etifoxine; Four plate test; GABA; Mice

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 PROPEN 1 ONE 1 (2 FLUOROPHENYL) 3 (4 HYDROXYPHENYL) O [2 (DIMETHYLAMINO)ETHYL]OXIME; 8 [5 2,4 DIMETHOXY 5 (4 TRIFLUOROMETHYLPHENYLSULFONAMIDO)PHENYL 5 OXOPENTYL] 1,3,8 TRIAZASPIROL[4,5]DECAINE 2,4 DIONE; ETIFOXINE; GABAERGIC RECEPTOR AFFECTING AGENT; N 3 PYRIDINYL 3,5 DIHYDRO 5 METHYLBENZO[1,2 B:4,5 B]DIPYRROL 1[2H]CARBOXAMIDE; RS 10 2221; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; SR 46349 B; UNCLASSIFIED DRUG; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 4-IODO-2,5-DIMETHOXYPHENYLISOPROPYLAMINE; AMPHETAMINE DERIVATIVE; ANXIOLYTIC AGENT; DIAZEPAM; OXAZINE DERIVATIVE; PROTEIN SUBUNIT; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG PROTEIN BINDING; GABAERGIC SYSTEM; LIGAND BINDING; LOCOMOTION; MOUSE; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SWISS WEBSTER MOUSE; TRANQUILIZING ACTIVITY; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; DRUG POTENTIATION; ELECTRIC SHOCK; MALE; METABOLISM;

AMPHETAMINES; ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DIAZEPAM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROSHOCK; LOCOMOTION; MALE; MICE; OXAZINES; PROTEIN SUBUNITS; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 77249145285     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.11.046     Document Type: Article

References (43)

1. Abi-Saab W.M., Bubser M., Roth R.H., and Deutch A.Y. 5-HT2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology 20 (1999) 92-96
2. Aron C., Simon P., Larousse C., and Boissier J.M. Evaluation of a rapid technique detecting minor tranquillizers. Neuropharmacology 10 (1991) 459-469
3. Boissier J.R., and Simon P. Action de la caféine sur la motilité spontanée de la souris. Arch Int Pharmacodyn 158 (1965) 212-221
4. Boissier J.R., Simon P., Zaczinska M., and Fichelle J. Experimental psychopharmacologic study of a new psychotropic drug, 2-ethylamino-6-chloro-4-methyl-4-phenyl-4H-3,1benzoxazine. Therapie 27 (1972) 325-338
5. Chiang C., and Aston-Jones G. A 5-hydroxytryptamine2 agonist augments gamma-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons. Neuroscience 54 (1993) 409-420
6. Cozzi N.V., and Nichols D.E. 5-HT2A receptor antagonists inhibit potassium-stimulated gamma-aminobutyric acid release in rat frontal cortex. Eur J Pharmacol 309 (1996) 25-31
7. Dumas S., and Vujasinovic T. Etifoxine et circuit des émotions. L'encéphale Suppl. 1 (2008) S21-S27
8. Feng J., Cai X., Zhao J., and Yan Z. Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons. J Neurosci 21 (2001) 6502-6511
9. Gao B., Fritschy J.M., Benke D., and Mohler H. Neuron-specific expression of GABAA-receptor subtypes: differential association of the alpha 1- and alpha 3-subunits with serotonergic and GABAergic neurons. Neuroscience 54 (1993) 881-892
10. Griffiths J.L., and Lovick T.A. Co-localization of 5-HT 2A-receptor- and GABA-immunoreactivity in neurones in the periaqueductal grey matter of the rat. Neurosci Lett 326 (2002) 151-154
11. Halasy K., Miettinen R., Szabat E., and Freund T.F. GABAergic interneurons are the major postsynaptic targets of median raphe afferents in the rat dentate gyrus. Eur J Neurosci 4 (1992) 144-153
12. Hamon A., Morel A., Hue B., Verleye M., and Gillardin J.M. The modulatory effects of the anxiolytic etifoxine on GABA(A) receptors are mediated by the beta subunit. Neuropharmacology 45 (2003) 293-303
13. Hascoët M., Bourin M., Colombel M.C., Fiocco A.J., and Baker G.B. Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice. Pharmacol Biochem Behav 65 (2000) 339-344
14. Heldt S.A., and Ressler K.J. Forebrain and midbrain distribution of major benzodiazepine-sensitive GABAa receptor subunits in the adult c57 mouse as assessed with in situ hybridization. Neuroscience 150 (2007) 370-385
15. Luttgen M., Ove Ogren S., and Meister B. Chemical identity of 5-HT2A receptor immunoreactive neurons of the rat septal complex and dorsal hippocampus. Brain Res 1010 (2004) 156-165
16. Massé F., Hascoët M., and Bourin M. Effect of GABAergic ligands on the anxiolytic-like activity of DOI (a 5-HT(2A/2C) agonist) in the four-plate test in mice. Eur Neuropsychopharmacol 17 (2007) 483-491
17. Massé F., Hascoet M., and Bourin M. alpha2-Adrenergic agonists antagonise the anxiolytic-like effect of antidepressants in the four-plate test in mice. Behav Brain Res 164 (2005) 17-28
18. Massé F., Hascoet M., Dailly E., and Bourin M. Effect of noradrenergic system on the anxiolytic-like effect of DOI (5-HT2A/2C agonists) in the four-plate test. Psychopharmacology (Berl) 183 (2006) 471-481
19. Massé F., Nic Dhonnchadha B.A., Hascoët M., and Bourin M. Anxiolytic-like effect of 5-HT(2) ligands and benzodiazepines co-administration: comparison of two animal models of anxiety (the four-plate test and the elevated plus maze). Behav Brain Res 177 (2007) 214-226
20. Massé F., Petit-Demouliere B., Dubois I., Hascoët M., and Bourin M. Anxiolytic-like effects of DOI microinjections into the hippocampus (but not the amygdala nor the PAG) in the mice four plates test. Behav Brain Res 188 (2008) 291-297
21. Micallef J., Soubrouillard C., Guet F., Le Guern M.E., Alquier C., Bruguerolle B., et al. A double blind parallel group placebo controlled comparison of sedative and amnesic effects of etifoxine and lorazepam in healthy subjects. Fundam Clin Pharmacol 15 (2001) 209-216
22. Nazar M., Siemiatkowski M., Czlonkowska A., Sienkiewicz-Jarosz H., and Plaznik A. The role of the hippocampus and 5-HT/GABA interaction in the central effects of benzodiazepine receptor ligands. J Neural Transm 106 (1999) 369-381
23. Nic Dhonnchadha B.A., Bourin M., and Hascoët M. Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety. Behav Brain Res 140 (2003) 203-214
24. Nic Dhonnchadha B.A., Hascoët M., Jolliet P., and Bourin M. Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice. Behav Brain Res 147 (2003) 175-184
25. Nic Dhonnchadha B.A., Ripoll N., Clénet F., Hascoët M., and Bourin M. Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test. Psychopharmacology 179 (2005) 418-429
26. Nguyen N., Fakra E., Pradel V., Jouve E., Alquier C., Le Guern M.E., et al. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol 21 (2006) 139-149
27. Petit-Demoulière B., Hascoët M., and Bourin M. Factors triggering abolishment of benzodiazepines effects in the four-plate test-retest. Eur Neuropsychopharmacol 18 (2008) 41-47
28. 2C receptors. Brain Res Mol Brain Res 23 (1994) 163-178
29. Rainnie D.G. Serotonergic modulation of neurotransmission in the rat basolateral amygdala. J Neurophysiol 82 (1999) 69-85
30. Ripoll N., Hascoet M., and Bourin M. Implication of 5-HT2A subtype receptors in DOI activity in the four-plates test-retest paradigm in mice. Behav Brain Res 166 (2006) 131-139
31. Ripoll N., Nic Dhonnchadha B.A., Sebille V., Bourin M., and Hascoet M. The four-plates test-retest paradigm to discriminate anxiolytic effects. Psychopharmacology (Berl) 180 (2005) 73-83
32. Ripoll N., Hascoet M., and Bourin M. The four-plates test: anxiolytic or analgesic paradigm?. Prog Neuro-Psychopharmacol Biol Psychiatry 30 (2006) 873-880
33. Ropert N., and Guy N. Serotonin facilitates GABAergic transmission in the CA1 region of rat hippocampus in vitro. J Physiol 441 (1991) 121-136
34. Schlichter R., Rybalchenko V., Poisbeau P., Verleye M., and Gillardin J. Modulation of GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine. Neuropharmacology 39 (2000) 1523-1535
35. Servant D., Graziani P.L., Moyse D., and Parquet P.J. Treatment of adjustment disorder with anxiety: efficacy and tolerance of etifoxine in a double-blind controlled study. Encephale 24 (1998) 569-574
36. Shen R.Y., and Andrade R. 5-Hydroxytryptamine2 receptor facilitates GABAergic neurotransmission in rat hippocampus. J Pharmacol Exp Ther 285 (1998) 805-812
37. Shi L., Argenta A.E., Winseck A.K., and Brunso-Bechtold J.K. Stereological quantification of GAD-67-immunoreactive neurons and boutons in the hippocampus of middle-aged and old Fischer 344 × Brown Norway rats. J Comp Neurol 478 (2004) 282-291
38. Varga V., Székely A.D., Csillag A., Sharp T., and Hajós M. Evidence for a role of GABA interneurones in the cortical modulation of midbrain 5-hydroxytryptamine neurones. Neuroscience 106 (2001) 783-792
39. Verleye M., André N., and Gillardin J.M. Lack of interaction between etifoxine and CRF1 and CRF2 receptors in rodents. Neurosci Res 56 (2006) 53-60
40. Verleye M., and Gillardin J.M. Effects of etifoxine on stress-induced hyperthermia, freezing behavior and colonic motor activation in rats. Physiol Behav 82 (2004) 891-897
41. Verleye M., Pansart Y., and Gillardin J. Effects of etifoxine on ligand binding to GABA(A) receptors in rodents. Neurosci Res 44 (2002) 167-172
42. Verleye M., Schlichter R., and Gillardin J.M. Interactions of etifoxine with the chloride channel coupled to the GABA(A) receptor complex. Neuroreport 10 (1999) 3207-3210
43. Verleye M., Schlichter R., Neliat G., Pansart Y., and Gillardin J.M. Functional modulation of gamma-aminobutyric acid(A) receptors by etifoxine and allopregnanolone in rodents. Neurosci Lett 301 (2001) 191-194